Annovis Bio (NYSE American: ANVS)
ANVS · NYSE American · United States
Share price · ANVS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ANVS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-19.0%
- 6 Nov 2026+26.3%
- 5 Nov 2026-44.7%
- 30 Oct 2026+10.8%
- 3 Sep 2026-18.8%
- 17 Aug 2026-5.9%
- 4 May 2026+14.0%
Nothing announced by ANVS that day or the session before.
- 9 Apr 2026-29.6%
- 25 Mar 2026-6.3%
- 16 Mar 2026+12.3%
Share of unusual movement by asset
For each asset, the share of ANVS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | APP/tau/alpha-synuclein/TDP-43 (translation)Small molecule | Alzheimer's DiseaseParkinson's Disease Early Alzheimer's Disease |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $16M | $2.8M | $9.5M-$16M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $12M | $19M | $15M-$22M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $17M | $14M | $18M-$9.0M operating cash flow | report ↗ |
| 2025-Q3 | — | $6.3M | $15M | $7.3M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | — | $5.2M | $17M | $6.2M-$5.1M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $5.0M | $22M | $5.5M-$8.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.7M | $13M | $13M-$3.2M operating cash flow | report ↗ |
| 2024-Q2 | — | $5.8M | $4.0M | $5.0M-$3.4M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $6.5M | $3.1M | $1.1M-$7.0M operating cash flow | report ↗ |
| 2023-Q3 | — | $14M | $6.3M | $15M-$9.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $8.3M | $16M | $9.5M-$9.6M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $7.8M | $17M | $9.7M-$12M operating cash flow | report ↗ |
| 2022-Q3 | — | $5.3M | $32M | $7.6M-$4.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $6.8M | $36M | $8.7M-$6.7M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $2.8M | $43M | $5.9M-$3.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.4M | $47M | $2.9M-$1.7M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $25M | $20M | $7.2M-$26M operating cash flow | report ↗ |
Annovis Bio reported revenue of $0M for fiscal 2025 (prior year $0M), R&D spend of $25.22M, up 26.1% YoY, and cash and equivalents of $19.53M at year-end. The company reported a net loss of $28.85M.
The company estimates its current cash will fund operations into the third quarter of 2026. During 2025, Annovis launched a pivotal Phase 3 trial of buntanetap in early Alzheimer’s disease, reached 65% enrollment by March 2026, received a positive DSMB safety recommendation at six months, reported biomarker data from prior AD and PD programs, and initiated an open-label extension study in Parkinson’s disease. It also transferred its patents to a new crystal form of buntanetap, extending intellectual property protection to 2047, and expanded its management team.
Insider transactions
Open-market activity, trailing 12 months: 17 purchases ($7.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Hoffman Michael B · director | Open-market purchase | 5,000,000 | $1.00 | $5.0M | Form 4 |
| 2026-11-06 | Hoffman Michael B · director | Open-market purchase (derivative) | 5,000,000 | $0.00 | $0 | Form 4 |
| 2026-05-20 | Hoffman Michael B · director | Open-market purchase | 2,562 | $1.75 | $4K | Form 4 |
| 2026-05-20 | Hoffman Michael B · director | Open-market purchase | 18,849 | $1.80 | $34K | Form 4 |
| 2026-05-20 | Hoffman Michael B · director | Open-market purchase | 54,933 | $1.90 | $104K | Form 4 |
| 2026-04-02 | Hoffman Michael B · director | Open-market purchase | 713,800 | $2.10 | $1.5M | Form 4 |
| 2025-12-08 | Hoffman Michael B · director | Open-market purchase | 30,000 | $4.34 | $130K | Form 4 |
| 2025-12-08 | Hoffman Michael B · director | Open-market purchase | 15,000 | $4.24 | $64K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 4.7M shares ($10.3M, 11.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 1,187,499 | $2.6M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 872,381 | $1.9M |
| 3 | TWO SIGMA INVESTMENTS, LP | 627,659 | $1.4M |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 347,600 | $775K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 247,513 | $552K |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 218,336 | $487K |
| 7 | NORTHERN TRUST CORP | 141,730 | $316K |
| 8 | BlackRock, Inc. | 139,533 | $311K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 132,042 | $294K |
| 10 | Merit Financial Group, LLC | 81,316 | $181K |
| 11 | STATE STREET CORP | 77,735 | $173K |
| 12 | GROUP ONE TRADING LLC | 69,663 | $155K |
| 13 | Sherry Group, Inc. | 57,270 | $128K |
| 14 | Wescott Financial Advisory Group, LLC | 41,607 | $93K |
| 15 | First National Trust Co | 40,000 | $89K |